دورية أكاديمية
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
| العنوان: | The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial. |
|---|---|
| المؤلفون: | Liu, Ming, Gu, Weijun, Chen, Li, Li, Yanbing, Kuang, Hongyu, Du, Jianling, Alvarez, Agustina, Lauand, Felipe, Souhami, Elisabeth, Zhang, Jiewen, Xu, Weiya, Du, Qin, Mu, Yiming |
| المصدر: | Diabetes Obes Metab ; ISSN:1463-1326 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | Chinese population, body weight, fixed‐ratio combination, glucagon‐like peptide‐1 receptor agonist, glycaemic control, hypoglycaemia, iGlarLixi, premixed insulin |
| الوصف: | To compare the efficacy and safety of a fixed-ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin, insulin degludec plus insulin aspart (IDegAsp), in Chinese people with type 2 diabetes (T2D) suboptimally controlled with oral antidiabetic drug(s) (OADs). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1111/dom.15724Test; https://pubmed.ncbi.nlm.nih.gov/38922731Test |
| DOI: | 10.1111/dom.15724 |
| الإتاحة: | https://doi.org/10.1111/dom.15724Test https://pubmed.ncbi.nlm.nih.gov/38922731Test |
| حقوق: | Diabetes, Obesity and Metabolism© 2024 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. |
| رقم الانضمام: | edsbas.52D29B73 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/dom.15724 |
|---|